ArticleFrontiers in medicine2025
Primary mucinous cystadenocarcinoma of the spleen: a case report and literature review.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumors of the spleen are uncommon, and most represent metastases from primary organs. Primary mucinous cystadenocarcinoma of the spleen is an extremely rare tumor. Only 11 cases have been reported in the literature. Case presentation: Herein, we present a case of primary mucinous cystadenocarcinoma in the spleen in a 50-year-old woman. Abdominal CT and MRI revealed a 9.5 × 6.5 cm mixed solid-cystic lesion with heterogeneous enhancement of the mural nodules and septations, with secondary extension abutting the gastric fundus and pancreatic tail. Notably, tumor biomarker profiling demonstrated remarkable increases in CA19-9 (>12,000 U/ml) and CEA (41.5 ng/ml) levels. Following splenectomy, histopathology revealed the mass to be a mucinous cystadenocarcinoma. Given that metastatic cystadenocarcinoma is relatively common, investigations were performed to evaluate the primary site of malignancy. A whole-body PET-CT scan did not reveal any metabolically active lesions in any part of the body. Neither upper gastrointestinal endoscopy nor colonoscopy revealed any primary malignant lesions. Hence, it was reported as a primary mucinous cystadenocarcinoma of the spleen. Conclusion: The need for presenting this case is due to its rarity and because mucinous cystadenocarcinoma can be a rare differential diagnosis in cases of malignant splenic cysts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.